IDH1 and neoplasm: Then, we conducted in vivo experiment where ivosidenib (50 mg kg−1), an IDH1 mutant enzyme inhibitor, was orally administered to TS603 (IDH1‐MUT) and U251 (IDH1‐WT) tumor‐bearing nude mice (Figure S20A, Supporting Information).